N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide
CAS : 33288-71-0
Ref. 3D-FA150607
1g | 991,00 € | ||
50mg | 136,00 € | ||
100mg | 190,00 € | ||
250mg | 396,00 € | ||
500mg | 687,00 € |
Informations sur le produit
- 2-pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-
- 4-[2-(5-Methyl-2-pyrazine carboxamido)ethyl]benzene sulfonamide
- 4-[2-(5-Methylpyrazine-2-carboxamido)ethyl]benzenesulfonamide
- 4-[2-(5-Methylpyrazinyl-2-carboxamido)ethyl]benzenesulfonamide
- 5-Methyl-N-[2-(4-sulfamoylphenyl)ethyl]pyrazine-2-carboxamide
- N-[2-[4-(Aminosulfonyl)phenyl]ethyl]-5-methyl-2-pyrazinecarboxamide
- Pyrazinecarboxamide, 5-methyl-N-(p-sulfamoylphenethyl)-
- Pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-
Fluoxetine is a potent inhibitor of the enzyme cytochrome P450 (CYP) 2C19. The inhibition of CYP2C19 by fluoxetine may lead to an increase in the plasma concentration of other drugs that are metabolized by this enzyme, such as glipizide and hydroxycyclohexyl. Fluoxetine inhibits human uric acid secretion and increases plasma concentrations of uric acid. This drug also inhibits human erythrocyte dihydropyrimidine dehydrogenase, leading to increased blood levels of pyrimidines, especially cytotoxic ones like 6-fluoro-3-indoxyl-beta-D-galactopyranoside. Fluoxetine has been shown to have a protective effect against acetaminophen toxicity in rats because it enhances the conversion of acetaminophen to its less toxic metabolite N-acetylcysteine.
Propriétés chimiques
Question d’ordre technique sur : 3D-FA150607 N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages